116 related articles for article (PubMed ID: 31899007)
1. Comparative analysis of the expression of metalloproteases (MMP-2, MMP-9, MMP-11 and MMP-13) and the tissue inhibitor of metalloprotease 3 (TIMP-3) between previous negative biopsies and radical prostatectomies.
Medina-González A; Eiró-Díaz N; Fernández-Gómez JM; Ovidio-González L; Jalón-Monzón A; Casas-Nebra J; Escaf-Barmadah S
Actas Urol Esp (Engl Ed); 2020 Mar; 44(2):78-85. PubMed ID: 31899007
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Matrix Metalloproteases by Artificial Intelligence Techniques in Negative Biopsies as New Diagnostic Strategy in Prostate Cancer.
Eiro N; Medina A; Gonzalez LO; Fraile M; Palacios A; Escaf S; Fernández-Gómez JM; Vizoso FJ
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108185
[TBL] [Abstract][Full Text] [Related]
3. Relationship between metalloprotease expression in tumour and stromal cells and aggressive behaviour in prostate carcinoma: Simultaneous high-throughput study of multiple metalloproteases and their inhibitors using tissue array analysis of radical prostatectomy samples.
Fernandez-Gomez J; Escaf S; Gonzalez LO; Suarez A; Gonzalez-Reyes S; González J; Miranda O; Vizoso F
Scand J Urol Nephrol; 2011 Apr; 45(3):171-6. PubMed ID: 21244194
[TBL] [Abstract][Full Text] [Related]
4. Correlation of serum and urinary matrix metalloproteases/tissue inhibitors of metalloproteases with subclinical allograft fibrosis in renal transplantation.
Hirt-Minkowski P; Marti HP; Hönger G; Grandgirard D; Leib SL; Amico P; Schaub S
Transpl Immunol; 2014 Jan; 30(1):1-6. PubMed ID: 24291496
[TBL] [Abstract][Full Text] [Related]
5. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue.
Brehmer B; Biesterfeld S; Jakse G
Prostate Cancer Prostatic Dis; 2003; 6(3):217-22. PubMed ID: 12970724
[TBL] [Abstract][Full Text] [Related]
6. Underexpression of MMP-2 and its regulators, TIMP2, MT1-MMP and IL-8, is associated with prostate cancer.
Reis ST; Antunes AA; Pontes-Junior J; Sousa-Canavez JM; Dall'Oglio MF; Piantino CB; Cruz JA; Morais DR; Srougi M; Leite KR
Int Braz J Urol; 2012; 38(2):167-74. PubMed ID: 22555040
[TBL] [Abstract][Full Text] [Related]
7. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
8. Loss of TIMP-1 immune expression and tumor recurrence in localized prostate cancer.
Reis ST; Viana NI; Iscaife A; Pontes-Junior J; Dip N; Antunes AA; Guimarães VR; Santana I; Nahas WC; Srougi M; Leite KR
Int Braz J Urol; 2015; 41(6):1088-95. PubMed ID: 26742965
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of stromal metalloproteases expression in patients with benign hyperplasia and prostate cancer.
Escaff S; Fernández JM; González LO; Suárez A; González-Reyes S; González JM; Vizoso FJ
J Cancer Res Clin Oncol; 2011 Mar; 137(3):551-5. PubMed ID: 20508949
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic value of stromal immunolabelling by MMP-2, MT1-MMP and TIMP-2 in clinically localized prostate cancer].
Semaan M; Jovenin N; Birembaut P; Menard J; Staerman F
Prog Urol; 2005 Apr; 15(2):250-4. PubMed ID: 15999602
[TBL] [Abstract][Full Text] [Related]
11. Tumor progression driven by pathways activating matrix metalloproteinases and their inhibitors.
Bodnar M; Szylberg Ł; Kazmierczak W; Marszalek A
J Oral Pathol Med; 2015 Jul; 44(6):437-43. PubMed ID: 25244188
[TBL] [Abstract][Full Text] [Related]
12. Expression of MMP-3, MMP-13, TIMP-2 and TIMP-3 in the VX2 carcinoma of the New Zealand white rabbit.
Mandic R; Dünne AA; Eikelkamp N; Ramaswamy A; Schulz S; Teymoortash A; Sesterhenn A; Moll R; Werner JA
Anticancer Res; 2002; 22(6A):3281-4. PubMed ID: 12530076
[TBL] [Abstract][Full Text] [Related]
13. miR-618: possible control over TIMP-1 and its expression in localized prostate cancer.
Ivanovic RF; Viana NI; Morais DR; Moura C; Silva IA; Leite KR; Pontes-Junior J; Nahas WC; Srougi M; Reis ST
BMC Cancer; 2018 Oct; 18(1):992. PubMed ID: 30340564
[TBL] [Abstract][Full Text] [Related]
14. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis.
Sutinen M; Kainulainen T; Hurskainen T; Vesterlund E; Alexander JP; Overall CM; Sorsa T; Salo T
Br J Cancer; 1998 Jun; 77(12):2239-45. PubMed ID: 9649139
[TBL] [Abstract][Full Text] [Related]
15. Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1, -2, and -3 in benign and malignant tumours of the salivary gland.
Nagel H; Laskawi R; Wahlers A; Hemmerlein B
Histopathology; 2004 Mar; 44(3):222-31. PubMed ID: 14987225
[TBL] [Abstract][Full Text] [Related]
16. Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients.
Sauer CG; Kappeler A; Späth M; Kaden JJ; Michel MS; Mayer D; Bleyl U; Grobholz R
Virchows Arch; 2004 Jun; 444(6):518-26. PubMed ID: 15088144
[TBL] [Abstract][Full Text] [Related]
17. Transperineal prostate biopsy detects significant cancer in patients with elevated prostate-specific antigen (PSA) levels and previous negative transrectal biopsies.
Dimmen M; Vlatkovic L; Hole KH; Nesland JM; Brennhovd B; Axcrona K
BJU Int; 2012 Jul; 110(2 Pt 2):E69-75. PubMed ID: 22093091
[TBL] [Abstract][Full Text] [Related]
18. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer.
Tunuguntla R; Ripley D; Sang QX; Chegini N
Gynecol Oncol; 2003 Jun; 89(3):453-9. PubMed ID: 12798711
[TBL] [Abstract][Full Text] [Related]
19. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer.
Michael M; Babic B; Khokha R; Tsao M; Ho J; Pintilie M; Leco K; Chamberlain D; Shepherd FA
J Clin Oncol; 1999 Jun; 17(6):1802-8. PubMed ID: 10561218
[TBL] [Abstract][Full Text] [Related]
20. Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma.
Kunz P; Sähr H; Lehner B; Fischer C; Seebach E; Fellenberg J
BMC Cancer; 2016 Mar; 16():223. PubMed ID: 26979530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
